Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
SEK 0.11
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
SpectraCure AB (publ) focuses on cancer treatment utilizing laser light sources and photo reactive drugs. It develops IDOSE software with interstitial photodynamic therapy system, which is in Phase II clinical trial for the treatment of solid tumors. The company was founded in 2003 and is based in Lund, Sweden.
Company Valuation
From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks.
Data is available to registered users only
Buy
Sell